Alphadyne Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Alphadyne Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131K	Buy	+10,182	New	+$130K	﹤0.01%	826

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alphadyne Asset Management's NTLA Position: Q1 2026 in Review

Alphadyne Asset Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 10,182 shares worth $131K. The stake represents ﹤0.01% of the portfolio and ranks #826 among its holdings.

302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Alphadyne Asset Management held 10,182 shares of Intellia Therapeutics worth $131K as of Q1 2026.
Intellia Therapeutics was a new Alphadyne Asset Management position in Q1 2026.
Intellia Therapeutics made up ﹤0.01% of Alphadyne Asset Management's portfolio in Q1 2026, its #826 holding.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Alphadyne Asset Management's 13F filing for Q1 2026, filed 15 May 2026.